Brokerages Set Biohaven Ltd. (NYSE:BHVN) Price Target at $63.15

Shares of Biohaven Ltd. (NYSE:BHVN - Get Free Report) have been assigned an average rating of "Buy" from the fifteen research firms that are presently covering the stock, MarketBeat reports. Fourteen research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $63.15.

BHVN has been the subject of a number of recent research reports. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Biohaven in a report on Tuesday, February 11th. They issued a "buy" rating and a $65.00 price objective for the company. TD Cowen upped their price target on Biohaven from $55.00 to $75.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. Cantor Fitzgerald reissued an "overweight" rating on shares of Biohaven in a research note on Tuesday, December 17th. HC Wainwright restated a "buy" rating and issued a $59.00 target price on shares of Biohaven in a report on Tuesday, December 17th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $61.00 price target (up previously from $58.00) on shares of Biohaven in a report on Wednesday, December 4th.

Insider Activity

In other news, Director John W. Childs purchased 29,000 shares of the business's stock in a transaction on Monday, December 30th. The stock was purchased at an average price of $35.94 per share, with a total value of $1,042,260.00. Following the acquisition, the director now directly owns 2,368,741 shares in the company, valued at approximately $85,132,551.54. The trade was a 1.24 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 16.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. HighTower Advisors LLC raised its stake in shares of Biohaven by 6.1% in the 4th quarter. HighTower Advisors LLC now owns 5,870 shares of the company's stock valued at $219,000 after buying an additional 335 shares in the last quarter. Franklin Resources Inc. raised its position in Biohaven by 0.5% in the third quarter. Franklin Resources Inc. now owns 79,705 shares of the company's stock worth $4,206,000 after purchasing an additional 412 shares in the last quarter. KBC Group NV lifted its stake in Biohaven by 24.5% during the third quarter. KBC Group NV now owns 2,250 shares of the company's stock worth $112,000 after purchasing an additional 443 shares during the period. Venturi Wealth Management LLC boosted its holdings in Biohaven by 19.1% during the third quarter. Venturi Wealth Management LLC now owns 3,117 shares of the company's stock valued at $156,000 after purchasing an additional 500 shares in the last quarter. Finally, FSC Wealth Advisors LLC grew its stake in shares of Biohaven by 3.3% in the 4th quarter. FSC Wealth Advisors LLC now owns 15,500 shares of the company's stock valued at $579,000 after purchasing an additional 500 shares during the period. 88.78% of the stock is currently owned by institutional investors and hedge funds.

Biohaven Trading Down 0.9 %

NYSE BHVN traded down $0.39 during trading on Friday, reaching $41.04. The company's stock had a trading volume of 116,330 shares, compared to its average volume of 890,437. The stock has a market capitalization of $4.15 billion, a PE ratio of -4.41 and a beta of 1.28. Biohaven has a 1-year low of $26.80 and a 1-year high of $62.21. The business has a 50-day moving average price of $38.53 and a 200-day moving average price of $42.71.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.